Search from website

Human IgG1-lambda antibody to SARS CoV-2 NP (clone 22F9)

 

Figure 1. Coomassie-stained SDS-PAGE analysis of monoclonal antibody to SARS-CoV-2 Nucleocapsid protein, clone 22F9. 4-12% gradient gel is used for analysis. Lane 1. Monoclonal antibody to SARS-CoV-2 Nucleocapsid protein, clone 22F9 (-DTT). Lane 2. Size marker. Lane 3. Monoclonal antibody to SARS-CoV-2 Nucleocapsid protein, clone 22F9 (+DTT).

       

Figure 2. HPLC analytical SEC for final product.

       

Figure 3. HPLC analytical SEC after 3 freeze-thaw cycles.

       

Figure 4. Octet RED96e analysis, antibody was loaded on sensor for capture of Nucleocapsid protein.

 

Select volume:

Quantity:

Catalogue #

R1-149-100

Name

Human IgG1-lambda antibody to SARS CoV-2 NP (clone 22F9)

Target

Nucleocapsid protein SARS-CoV-2

Target Description

Recombinant SARS-CoV-2 Nucleocapsid protein produced by CHO-based Icosagen Cell factory Ltd. proprietary suspension cell line

Clonality

Human monoclonal

Clone

22F9

Class

hIgG1

Reactivity

SARS-CoV-2 Nucleocapsid protein

Dissociation constant (KD)

< 1.0 x 10-12 M

Application

ELISA, WB

Kd:

< 1.0 x 10-12 M

ELISA:

0,08-0,16 µg/ml

WB:

0,5-1 µg/ml

Purification

Protein A affinity chromatography

Buffer

PBS pH 7.4

Shipping

Shipped at ambient temperature.

Storage

Store at -20 °C to -70 °C long term. Avoid multiple freeze-thaw cycles.

This product is for research use only

TECHNICAL ASSISTANCE

Please refer any technical questions to

technical.support@icosagen.com
error:
Shopping Cart